(Q50503410)

14 March 2018

title

Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. (English)

1 reference

14 March 2018

author name string

Tsutomu Kobayashi

1

1 reference

14 March 2018

Yasuhiko Tsutsumi

2

1 reference

14 March 2018

Natsumi Sakamoto

3

1 reference

14 March 2018

Hisao Nagoshi

4

1 reference

14 March 2018

Mio Yamamoto-Sugitani

5

1 reference

14 March 2018

Yuji Shimura

6

1 reference

14 March 2018

Shinsuke Mizutani

7

1 reference

14 March 2018

Yosuke Matsumoto

8

1 reference

14 March 2018

Kazuhiro Nishida

9

1 reference

14 March 2018

Shigeo Horiike

10

1 reference

14 March 2018

Naoko Asano

11

1 reference

14 March 2018

Shigeo Nakamura

12

1 reference

14 March 2018

Junya Kuroda

13

1 reference

14 March 2018

Masafumi Taniwaki

14

1 reference

14 March 2018

publication date

14 September 2012

1 reference

14 March 2018

Japanese Journal of Clinical Oncology

published in

1 reference

14 March 2018

volume

42

1 reference

14 March 2018

page(s)

1035-1042

1 reference

14 March 2018

issue

11

1 reference

14 March 2018

Diffuse large cell lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Revised response criteria for malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Targeted treatment and new agents in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS148

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYS148

1 reference

14 March 2018

release_in55vuo7ubhezhbtqofg4p57ui

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/in55vuo7ubhezhbtqofg4p57ui

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22984125

1 reference

14 March 2018